Type 2 diabetes is no longer a lifelong sentence; emerging research shows it can be reversed With strategic lifestyle changes ...

EMA accepts for review GSK’s MAA for depemokimab for use in asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 09:00 Hrs [IST] GSK plc announced ...

Learn how ordinary daily choices may be accelerating type 2 diabetes damage, and discover the vital changes that could save your organs from permanent harm.

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...

The submitted indications are for add-on maintenance treatment of asthma in adult and adolescent patients aged 12 years and older with type 2 inflammation characterised by an eosinophilic phenotype ...

The FDA has approved Ozempic to reduce kidney failure risk in people with type 2 diabetes and chronic kidney disease. Studies show it lowers kidney-related complications by 24 per cent. This offers ...